Berry Oncology recently announced the successful raising of nearly RMB 700 million in its Series B1 financing, led by China Merchants Capital, with support from existing shareholders Qiming Venture Partners and Legend Capital. Other investment institutions, including CICC Capital, E Fund Capital, Fujian Venture Investment Management Co., Ltd., and C&D Emerging Industry Investment, also participated in the funding.

CEC Capital Group served as the exclusive financial advisor for Berry Oncology in this transaction.

As a unicorn in the field of tumor early screening, Berry Oncology has attracted approximately RMB 1 billion in investment in less than a year, raising nearly RMB 2 billion from leading domestic funds since its establishment.

Berry Oncology is an oncology genetic testing company with a focus on tumor early screening. Since its inception, the company has established comprehensive genetic testing products and services for high-risk individuals and cancer patients.